December 4th, 2024 (Shanghai) — We are glad to announce that Kyu-Tae Kim, Ph.D., the Chief Business Officer of Pharos iBio Co. Ltd., will be presenting at the ACCESS CHINA Partnering Forum @ JPM on January 7th-9th, and 21st-23rd, 2025. ACCESS CHINA Biotech Forum is the largest corporate access event between Asia and the Western biopharma industry.
About Pharos iBio Co. Ltd.
Pharos iBio is a clinical-stage biotech company developing innovative treatments for rare and refractory diseases using its proprietary AI-driven drug discovery platform, Chemiverse®. This platform integrates nine advanced modules, including DeepRECOM™, which predicts drug efficacy and identifies novel targets, and ChemGEN™, which generates new drug candidates through ultra-fast virtual screening.
Pipeline Highlights:
PHI-101: A next-generation FLT3 inhibitor targeting mutations in AML. Phase 1 trials have demonstrated efficacy, safety, and tolerability for relapsed/refractory (R/R) AML. A global Phase 2 trial for R/R AML is planned for early 2025, alongside ongoing trials for MRD-positive AML patients. Additionally, PHI-101 is in a Phase 1 trial for ovarian cancer, leveraging its CHK2 inhibition to block DNA damage repair pathways.
PHI-501: A pan-RAF/DDR inhibitor for solid tumors, showing strong preclinical efficacy against RAF/NRAS mutations and overcoming treatment resistance in colorectal cancer and melanoma.
By harnessing AI and big data, Pharos iBio delivers precision solutions to address critical unmet medical needs.
About the speaker
Kyu-Tae Kim is the Chief Business Officer (CBO) at Pharos iBio, a biotechnology company leveraging AI-driven big data to develop novel small molecule inhibitors. He oversees BD and licensing activities for the company. In addition, he serves as the co-CEO of Pharos Therapeutics Pty Ltd, Pharos iBio’s wholly owned Australian subsidiary, which focuses on clinical trials and R&D collaborations in Australia.
Before joining Pharos iBio, He was the Chief Scientific Officer and Head of BD & Licensing at AbClon, a biotech company specializing in therapeutic antibodies and CAR-T cell therapies. He played a key role in the successful IPOs of both Pharos iBio and AbClon on the KOSDAQ, leveraging his extensive expertise in research and business operations.
He is a seasoned biotechnology professional with a proven track record of leading successful technology transfer deals in both domestic and international markets.
About ACCESS CHINA Partnering Forum
ACCESS CHINA Partnering Forum @ JPM is scheduled to be held on January 7th-9th, and 21st-23rd, 2025, via Zoom webinar. This event helps biotechs/pharmas efficiently present their assets in front of 500+ healthcare companies and VCs online. During the event, the audience can have access to innovative pharma and healthcare products from worldwide.
Conference Name: ACCESS CHINA Partnering Forum
Date & Time: January 7-9 (Live), and 21-23(VoD), 2025, China time
Content: Keynote Speeches, Panel Discussion, Company Presentations, ChemPartner-ACCESS CHINA Dinner Reception
Scale: Expected 500+ participants Online; 100 company roadshows
Participants: Pharma/Biotech senior management and BDs
View more information at https://biotochina.org/
Contact us:
To register for ACCESS CHINA online, please visit: ACCESS CHINA Biotech Forum
For more information, please contact:
Wendi Xiang
BioToChina.org 